JP2023537222A5 - - Google Patents

Info

Publication number
JP2023537222A5
JP2023537222A5 JP2023503448A JP2023503448A JP2023537222A5 JP 2023537222 A5 JP2023537222 A5 JP 2023537222A5 JP 2023503448 A JP2023503448 A JP 2023503448A JP 2023503448 A JP2023503448 A JP 2023503448A JP 2023537222 A5 JP2023537222 A5 JP 2023537222A5
Authority
JP
Japan
Prior art keywords
superantigen
cancer
superantigen conjugate
conjugate according
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537222A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2021/050882 external-priority patent/WO2022018726A1/en
Publication of JP2023537222A publication Critical patent/JP2023537222A/ja
Publication of JP2023537222A5 publication Critical patent/JP2023537222A5/ja
Pending legal-status Critical Current

Links

JP2023503448A 2020-07-20 2021-07-20 癌を治療するための方法および組成物における使用のためのスーパー抗原コンジュゲート Pending JP2023537222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053859P 2020-07-20 2020-07-20
US63/053,859 2020-07-20
PCT/IL2021/050882 WO2022018726A1 (en) 2020-07-20 2021-07-20 Superantigen conjugate for use in methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
JP2023537222A JP2023537222A (ja) 2023-08-31
JP2023537222A5 true JP2023537222A5 (cg-RX-API-DMAC7.html) 2024-07-24

Family

ID=79728646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023503448A Pending JP2023537222A (ja) 2020-07-20 2021-07-20 癌を治療するための方法および組成物における使用のためのスーパー抗原コンジュゲート

Country Status (9)

Country Link
US (1) US20230285588A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181965A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023537222A (cg-RX-API-DMAC7.html)
KR (1) KR20230085904A (cg-RX-API-DMAC7.html)
CN (1) CN116490521A (cg-RX-API-DMAC7.html)
AU (1) AU2021313881A1 (cg-RX-API-DMAC7.html)
CA (1) CA3173909A1 (cg-RX-API-DMAC7.html)
IL (1) IL299950A (cg-RX-API-DMAC7.html)
WO (1) WO2022018726A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN120847420B (zh) * 2025-09-23 2025-12-02 天津医科大学总医院 T细胞亚群在制备评估b细胞耗竭疗法试剂盒中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061694A1 (en) * 2001-05-10 2003-07-31 Seattle Genetics, Inc. Immunosuppression of the humoral immune response by anti-cd20 antibodies
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
EP3411409B1 (en) * 2016-01-10 2025-10-08 Neotx Therapeutics Ltd. Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy

Similar Documents

Publication Publication Date Title
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체
WO2019140150A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2022174775A1 (en) Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
JP2023011902A (ja) Pd-1阻害剤を投与することにより子宮頸がんを処置する方法
JP2023548051A (ja) 肺がんのためのlag-3アンタゴニスト療法
JP2024519907A (ja) 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用
Huet et al. Targeted nanofitin-drug conjugates achieve efficient tumor delivery and therapeutic effect in an EGFRpos mouse xenograft model
EP4676541A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
WO2025078686A1 (en) Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer
JP2025542297A (ja) 肺癌の組み合わせ療法
AU2024286132A1 (en) Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies
US20230061858A1 (en) Treatment with site specific her2 antibody-drug conjugates
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
US20260132195A1 (en) Anti-il-2 antibody combinations and methods of use thereof
RU2861651C2 (ru) Введение ингибиторов pd-1 для лечения рака кожи
Toldrà et al. American Association for Cancer Research (AACR)-113th Annual Meeting. New Orleans/Virtual-April 8-13, 2022
WO2026039321A1 (en) Methods for treating prostate cancer
Gennigens et al. Emerging therapies in gynaecological cancers (part 1): Locally advanced and metastatic cervical cancer
Teicher Antibody drug and radionuclide conjugates for GI cancers
WO2025256641A1 (zh) 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤
EP4297782A1 (en) Methods of treating lung cancer by administering a pd-1 inhibitor
WO2026046410A1 (zh) 一种抗体药物偶联物与免疫检查点抑制剂的组合
Lézard Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer